Oncology and Immunotherapy
In cancer context, the immunomonitoring enables for a comprehensive assessment of an immune repertoire. It also enables identification of an immune response to tumor growth and metastases by characterizing the tumor infiltrating lymphocyte (TIL) population in a sample.
Unmask intratumoral heterogeneity, and trace transcriptomic modulators of clonal evolution within tumors and across cancer types.
Uncover the influence of tumor immune infiltrate on therapeutic response and identify the transcriptomic programs driving diverse phenotypes and developmental trajectories.
Advance immunotherapies by characterizing immune cell modulation in tumor progression. Define the receptor repertoire of infiltrating and peripheral immune cells mediating anti-tumor responses and predicte and monitore immune related adverse events.
Discover novel therapeutic targets, explore how therapeutics modulate cell populations and states within the tumor microenvironment, and understand resistance mechanisms governed by transcriptomic.
Identifying predictive and prognostic biomarkers
Monitoring responses to therapy/treatment See our recent webinars about the application of immunoSEQ Technology in oncology research.